Till now, there was still controversy, and few studies explored the possibility of concurrent PD-1 inhibitor and chemoradiotherapy for the R/M HNSCC patients, so we aimed to design this trial and find the results out. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.